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ABSTRACT We report on the application of fluorescence correlation spectroscopy (FCS) to observe the interaction between
thrombin and thrombin inhibitors. Two site-specific fluorescent labels were used to distinguish between inhibitors directed to
the active site, the exosite, or both binding sites of thrombin. For several well-known inhibitors of thrombin, the binding sites
observed by FCS correspond to previous studies. The interaction of the recently discovered thrombin inhibitor ornithodorin
from the tick Ornithodorus moubata with thrombin was investigated. It was found that this inhibitor, like hirudin and rhodniin,
binds to both the active site and exosite of thrombin simultaneously. This study shows the feasibility of FCS as a sensitive
and selective method for observing protein-ligand interactions. As an additional technique, simultaneous labeling with both
fluorescent labels was successfully demonstrated.
INTRODUCTION
Fluorescence correlation spectroscopy (FCS) is an analyti-
cal tool that uses number fluctuations of fluorescent mole-
cules (or particles) in a very small observation volume (the
confocal volume of a set-up analogous to confocal laser
microscopy) to obtain information on the diffusive proper-
ties of these molecules. Molecular interactions that lead to
the formation of a complex between the fluorescent mole-
cules and other molecules show up in a reduced diffusion
constant of the fluorescent molecules, as the thermal diffu-
sion of the complex will be slower than that of each com-
ponent. Together with the high sensitivity and the spectral
selectivity, the ability to derive diffusion coefficients of the
observed fluorescent molecules, and therefore to distinguish
between different states of these molecules without physical
separation, makes FCS an interesting technique for many
problems in biochemistry (Rigler, 1995). FCS, conceived
more than 20 years ago (Magde et al., 1972), has recently
seen a surge in interest. There are two main reasons for this
surge in interest.
First, technical advances (Thompson, 1991), like
progress in confocal laser microscopy and high-quantum-
efficiency solid-state light detectors, have made it possible
to carry out FCS measurements with low background and
short measurement durations at very low concentrations of
the analyte, even down to single molecule detection (Rigler,
1995).
Second, fluorescent techniques are becoming more im-
portant in the discovery of new lead structures for drugs.
This discovery still involves brute-force testing of large
compound libraries for every new pharmaceutical target,
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despite the considerable progress of more knowledge-based
approaches, like molecular modeling (Campbell, 1996;
Bohm et al., 1996). With the advent of new synthesis
strategies like combinatorial chemistry (Campbell, 1996),
the size of compound libraries is seeing a vast expansion. To
screen these large compound libraries, it is necessary to
develop fast screening methods. Many screening methods
for new drugs currently employed are heterogeneous; that
is, they rely on a physical separation of bound and unbound
ligands. This separation is time consuming because of re-
petitive pipetting and washing steps. An approach to avoid-
ing this would be a homogeneous assay principle like FCS,
concentrating on a change of physical parameters of fluo-
rescent reference compounds, like rotational or translational
diffusion constants. Such homogeneous assay principles can
detect the release of the fluorescent reference compound
from the target through competition from a compound to be
tested without separating bound from unbound reference
compounds, thus offering the promise of fast assays. The
goal of the present work is to investigate in detail the
feasibility of homogeneous FCS assays for a well-known
target.
THROMBIN AND INHIBITORS
The biochemical system investigated is shown in Fig. 1. We
employed thrombin as a model system to evaluate FCS as
an analytical technique for drug screening. Thrombin (m =
39 kDa) is the central protease in the blood coagulation
cascade (Jackson, 1980; Davie et al., 1991). Thrombin cuts
two small peptides from the protein fibrinogen, forming
fibrin, which, in turn, polymerizes. To achieve this, throm-
bin is equipped with two binding sites. The exosite is a
positively charged surface area that binds fibrinogen and
orients it according to distance and location toward the
active site. The active site contains a catalytic pocket of the
trypsin type. Two peptide loops restrict the access of pro-
teins to this binding site and therefore are responsible for the
high specificity of thrombin.
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several thrombin inhibitors are known. The inhibitors used
in this study are also shown in Fig. 1. Hirudin, rhodniin, and
ornithodorin are proteins isolated from blood-sucking ani-
mals. Hirulog and the hirudin peptides are shorter parts of
hirudin. The natural proteins and hirulog are known to bind
to both binding sites, the small-molecular-weight com-
pounds to the active site only, and the hirudin peptides only
to the exosite (Dodt, 1995). As shown by recent crystal
structure studies, ornithodorin should bind to both active
site and exosite (van de Locht et al., 1996).
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MATERIALS AND METHODS
FCS
All measurements were made on a homemade FCS apparatus, based on a
modified commercial confocal laser scan microscope (type Leica DM-RB;
Leica GmbH, Heidelberg, Germany). The set-up is similar to one recently
described in the literature (Rigler et al., 1993), so only a short description
is given here. The light of a 20-mW argon laser (488 or 514 nm) is coupled
to a single-mode optical fiber and passes through the illumination pinhole
(diameter 30 ,m) onto a partially reflective (20%) mirror. The reflected
light is focused by a water immersion microscopy objective (magnification
5OX, NA 0.75; Leica) into the sample. Absolute light intensities at the
point of focus are between 0.05 and 0.5 mW. The samples are presented in
rectangular glass capillaries (Microslide; Camlab, Cambridge, England;
inner dimensions 1.000 ,um X 200 ,um, wall thickness 185 ,um, length 5
cm, sample volume 10-20 ,u). The excited fluorescence is collected by the
objective and focused through the partially reflective mirror (80% trans-
mission) and the detection pinhole (variable diameter, set to 130 ,um in this
study) onto the sensitive area of a silicon avalanche diode module (SPCM
200; EG&G Instruments, Princeton, NJ). The electric signal of this detector
is fed into a hardware correlator (ALV-5000; ALV, Langen, Germany).
The standard measurement duration for this study was 60 s, at signal count
rates of 10-100 kHz and a background of 1-2 kHz.
Data evaluation procedure
The data evaluation procedure in FCS is similar to the one used for photon
correlation spectroscopy (or dynamic light scattering) (Beme and Pecora,
1976) and has been described in the literature (Rigler et al., 1993).
In short, the direct result of a FCS measurement, the autocorrelation
function (ACF) G(t) of the observed fluorescence intensity, is fitted to the
equation
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FIGURE 1 Thrombin inhibitors and reference compounds used in this
study.
As thrombin is responsible for the fibrin polymerization
and in part for the formation of blood clots in different
coagulation-related diseases, it is a well-studied target, and
G(t) =1 I /T)) (1)
where N is the average number of fluorescent molecules and T is the
average duration of their stay in the observation volume. For molecules
moving under thermal diffusion, T is given by
r2
= 4D (2)
where D is the thermal diffusion coefficient of the molecules and r is the
radial width of the laser profile (Ile point). The value of r must be obtained
by calibrating the instrument once with a sample with a known diffusion
coefficient. To give more intuitively accessible results, the diffusion coef-
ficients in this study are converted to apparent hydrodynamic diameters
according to the Einstein equation
kT
d=3D (3)
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active site inh. AS1-1
active site inh. ASI-2
M
6.5 kD natural inhibitor (Hiruda medicinalis)
11 kD natural inhibitor (Rhodnius prolixus)
12 kD natural inhibitor (Ormithodoruis moubata)
C-terminal sequence of HirLudin, linked to
3 kD
active-site inhibitor
3 C-terminal sequences of Hirudin
1471 D 1: N-acetyl-FEEIPEEYLQ-COOH
1644 D 2: N-acetyl-DFEEIPEEYLQ-COOH
3: N-acetyl-HNDGFEEIPEEYLQ-COOH
1835
394 D (see formuila 1)
394 D (see formula 2)
Fluorescent reference compounds
ASI-2' (active site) 872 D FITC-labeted active site inh ASI-2
JR-Sym (exosite) 5600 D Rhodamine labeled DNA oligomer
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where d is the hydrodynamic diameter of the molecule, k is the Boltzmann
constant, T is the absolute temperature, and q is the viscosity of the
medium.
In the literature, there are several expansions of Eq. 1 that account for
deviations of the real experiment from the idealized one, for which Eq. 1
is derived. In our study, however, these expansions are neglected, and the
data are evaluated for the simple case of Eq. 1, with its two free parameters
N and T. We chose to do so after evaluation with more complicated
equations that include the above expansions gave unstable results with our
experimental data. (For the expanded data evaluation, we followed the
formula in Widengren et al. (1994). The expansions take into account 1)
the finite extent of the observation volume along the optical axis, 2) the
pumping of the fluorophores into the triplet state, and 3) the presence of
bound and unbound fractions of the reference compound. The programs
used to perform the nonlinear curve fitting were 1) a home-written program
for nonlinear least-square fit of FCS data, 2) the nonlinear curve-fitting
routine of the program package SigmaPlot by Jandel Corporation, and 3)
the program FCS ACCESS by EVOTEC BioSystems GmbH (Hamburg,
Germany), recently made available to us by Carl Zeiss Jena GmbH.)
So for each ACF, the fit to Eq. 1 yields two parameters: the average
number N of fluorescent molecules observed, and their average time T of
stay in the observation volume. T is converted into a hydrodynamic size by
using Eqs. 2 and 3. To give absolute numbers, the instrumental value of r
is calibrated with Rhodamin 6G as a molecule of known diffusion coeffi-
cient. (The hydrodynamic sizes given in this study are obtained by cali-
bration of the instrument with an aqueous solution of the fluorescent dye
Rhodamin 6G. The diffusion coefficient of R6G at 22°C is assumed to be
D = 2.8 - 10-10 m2/s, corresponding to a hydrodynamic radius of 1.60 nm.
The calibration of our instrument then gives values of r = 250 nm and r =
270 nm for laser wavelengths of 488 nm and 514 nm, respectively. When
a noticeable triplet fraction is present, we ignore the first few channels of
the ACF in the data evaluation. Data evaluation for the more photostable
reference compound JR-Sym* with the rhodamine label starts at a ACF
time lag of 6 p,s, for the less photostable reference compound ASI-2* with
the fluorescein label at a 6- or 12-,us time lag. At greater time lags than
these, the triplet influence in the ACF is negligible.)
For a mixture of two components A and B with the same fluorescent
properties but different sizes (bound/free reference compound), the mea-
sured average hydrodynamic size daverage from the simple fit of Eq. 1 can
be calculated from the sizes of the individual components:
log(daverage) -XA1g(dA) + XBlog(dB) (4)
where XA and XB are the molar fractions of components A and B, respec-
tively. Equation 4 is strictly valid only for dA and dB that are very close
together. Computer simulations of noise-free two-component ACFs have
shown, however, that the error obtained with Eq. 4 when compared to the
true two-component evaluation is less than 2%, if the size difference of the
two compounds is less than a factor of 3, as is the case in our experiment.
In the case of an ideal, noise-free ACF, the molar fractions x and individual
times T of a mixture of two components A and B with the same fluorescent
properties can be obtained by fitting the ACF to the equation (Rigler et al.,
1993b)
G(t) = 1 + t/TA 1++tXB )
Thrombin and inhibitors
This study was carried out using commercial bovine thrombin (Sigma no.
T 6634). Solutions of 10-50 ,LM in isotonic NaCl solution were divided
into aliquots, stored at -180C, and thawed before each experiment. Hiru-
din (Markwardt, 1955) was supplied by Dr. Schweden, BASF-AG. Rhod-
niin was prepared according to the methods of Friedrich et al. (1993) and
van de Locht et al. (1995). Ornithodorin was prepared directly from the tick
Ornithodorus moubata according to the method of van de Locht et al.
(1996) and Otte et al., (manuscript in preparation). Hirulog and the hirudin
peptides 1-3 were synthesized on a standard peptide synthesizer (Dodt,
1995).
Active site inhibitors ASI-1 and ASI-2 were synthesized by standard
organic synthesis protocols and characterized by mass spectrometry and
NMR.
All experiments were carried out in isotonic NaCl solution (145 mM
NaCl) or phosphate buffer at pH 7.4 at room temperature (22°C) without
further temperature control.
Fluorescent reference compounds
We synthesized two fluorescent reference compounds (ASI-1* and ASI-
2*), directed to the active site and the exosite of thrombin, respectively.
The fluorophores of these compounds were chosen to be well separated in
excitation and emission wavelengths, so that each of them can be addressed
separately by using suitable laser wavelengths and filter combinations.
The fluorescent reference compound directed to the active site (ASI-2*)
was derived from the active site inhibitor ASI-2. Forty milligrams of
ASI-2 (466.41 D, 85.8 ,umol) was incubated with 60.8 mg
fluorescein(5,6)succinimide ester (128.7 ,umol) in 2 ml N,N-dimethylfor-
amide and 9 ,ul triethylamine (86 ,umol) for -16 h at room temperature.
The reaction mixture was then diluted with 2 N,N-dimethylforamide and
applied to a C18-reversed phase HPLC separation (Macherey&Nagel RP
100/5 C, 18 ml, 4 mm diameter, 250 mm main column length, and a
precolumn of 4 mm diameter and 11 mm length) on a Merck/Hitatchi
HPLC system. For separation a linear gradient was used. (solvent A H20
with 0.1% formic acid, solvent B CH3CN with 0.1% formic acid). The
labeled active site inhibitor ASI-2* was detected as a new thrombin-
inhibiting fraction. Mass spectrometry revealed the expected molecular
weight.
The fluorescent reference compound directed to the exosite (JR-Sym*)
is a rhodamine-labeled DNA oligomer known from the literature (Wu et
al., 1992). The DNA aptamer is synthesized on an Applied Biosystems
394-Synthesizer according to the manufacturers' guidelines with the se-
quence JR-Sym: GG1TGGTGTGGTTGG with a 5' aminolink. As a con-
trol we synthesized the sequence JR-Neg: GGTGGTGGTTGTGGT (Wu et
al., 1992). The rhodamine (ROX, ABI no. 400980) was coupled to the 5'
end in a carbonate buffer (0.5 M NaHCO3/Na2CO3, pH 9) overnight. The
labeled oligomers were purified by gel electrophoresis. The coupling of the
dye was checked by spectral analysis of the end product, comparing
absorption at 260 nm (DNA band) and 586 nm (ROX band).
RESULTS
Reference compounds
In a first step of the experiments, the binding of the refer-
ence compounds to thrombin was observed. Fig. 2 shows
the measured hydrodynamic sizes of the reference com-
pounds versus the concentration of thrombin. At the starting
point and at the end point of the titration curves, the mea-
sured hydrodynamic sizes correspond to the size of the free
and the bound reference compounds, respectively. The solid
lines in Fig. 2 are a fit of the data to the model of a
two-component complexation in chemical equilibrium, with
the resulting observed hydrodynamic size calculated ac-
cording to Eq. 4. The values for the dissociation constant of
the reference compounds obtained from the fit are 200 nM
for JR-Sym* and 500 nM for ASI-2*. The scrambled DNA
aptamer JR-Neg* shows no complexation with thrombin.
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FIGURE 2 Measured hydrodynamic size of the reference compounds
JR-Sym* (0) and ASI-2* (0) versus thrombin concentration. (To give
more intuitively accessible results, all experimental data in this study are
given as apparent hydrodynamic diameters, converting the direct result of
the fit to the ACF, T, according to Eqs. 2 and 3.) Concentration of the
reference compounds was 5 nM for JR-Sym* and 13 nM for ASI-2*. The
solid lines are a fit to a two-component complexation model in chemical
equilibrium with dissociation constants of 200 nM (0) and 500 nM (0),
respectively.
Competition experiments
We form a complex by incubating a small amount of one of
the reference compounds with an excess of thrombin. To
this complex, various amounts of thrombin inhibitors are
added and the apparent hydrodynamic size of the fluores-
cent species is monitored with FCS. If the reference com-
pound in the complex with thrombin is replaced by the
inhibitor, the hydrodynamic size of the reference compound
measured by FCS is reduced.
The standard protocol of the experiments is as follows:
Solutions (0.5-5 ml of 5-50 nM) of the reference com-
pounds were incubated with 1-50 ,tM thrombin for 30 min.
The sample is then divided into several aliquots. A certain
concentration of the thrombin inhibitor under investigation
is added to one aliquot. After an additional incubation time
of 30 min, part of the aliquot is transferred to a microslide
and measured in the FCS setup. Typically, five measure-
ments of 60 s duration each are made for each sample. This
procedure is repeated for several inhibitor concentrations.
Fig. 3 shows the result of two such measurement series
for the thrombin inhibitor rhodniin. The apparent hydrody-
namic sizes of the reference compounds drop from their
maximum value of 6.2 nm (JR-Sym*) and 4.7 nm (ASI-2*)
for the thrombin/reference compound complex without
rhodniin to 4.1 nm (JR-Sym*) and 1.8 nm (ASI-2*) at high
rhodniin concentrations. These end sizes correspond to the
sizes of the free reference compounds. Similar experiments
were carried out for all of the thrombin inhibitors of Fig. 1.
Fig. 4 shows the result for the active site inhibitors ASI-1
and ASI-2. The complex between JR-Sym* and thrombin is
not broken up by the addition of ASI-1 or ASI-2. Fig. 5
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FIGURE 3 Measured hydrodynamic size of the reference compounds
JR-Sym* (-) and ASI-2* (0) versus concentration of the thrombin inhib-
itor rhodniin added to a previously formed complex of the reference
compounds with thrombin. Concentrations: 3.3 ,M thrombin (both exper-
iments), 33 nM JR-Sym*, 13 nM ASI-2*.
shows the respective results for the recently discovered
thrombin inhibitor ornithodorin.
Table 1 gives an overview of the results of all competi-
tion experiments. Listed are the measured hydrodynamic
sizes of the reference labels at high concentrations of the
respective inhibitors, compared to the sizes for the reference
compounds themselves and their complexes with thrombin.
The errors indicated are standard deviations of at least five
repetitions of each measurement.
Double labeling
In one series of experiments, thrombin was incubated with
both reference labels at the same time. Measurements of
each sample were taken at the two wavelengths 488 nm and
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FIGURE 4 Measured hydrodynamic size of the reference compounds
JR-Sym* (-) and ASI-2* (0) versus concentration of the thrombin active
site inhibitors ASI-1 ( ) and ASI-2 (- - -) added to a previously formed
complex of the reference compounds with thrombin. Concentrations: 3.3
,uM thrombin (both experiments), 33 nM JR-Sym*, 13 nM ASI-2*.
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FIGURE 5 Measured hydrodynamic size of the reference compounds
JR-Sym* (0) and ASI-2* (0) versus concentration of the thrombin inhib-
itor ornithodorin added to a previously formed complex of the reference
compounds with thrombin. Concentrations: 3.3 ,.LM thrombin (both exper-
iments), 33 nM JR-Sym*, 13 nM ASI-2*.
514 nm, selective for ASI-2* and JR-Sym*, respectively.
Otherwise, the experiments were performed in the same
way as described above for single labeling. Table 2 shows
the results of this double-labeling experiment.
DISCUSSION
The data of Fig. 2 show that FCS is a suitable method for
monitoring the formation of molecular complexes in a ho-
mogeneous assay without separation steps. The measured
hydrodynamic sizes of 7 nm for the bound state and 4 nm
TABLE I Summary of competition experiments
(single labeling)
Binding site: Active site Exosite
Reference compound: ASI-2* JR-Sym*
measured size measured size
Inhibitor (nm) (nm)
Hirudin 1.8 0.2 4.1 0.4
Rhodniin 1.7 0.3 4.1 0.3
Ornithodorin 2.1 0.3 3.7 0.4
Hirulog 1.8 0.2 4.8 0.3
Hirudin peptide 1 4.3 + 0.5 4.5 0.5
Hirudin peptide 2 4.1 0.6 5.0 0.7
Hirudin peptide 3 4.1 0.4 4.5 0.7
ASI-1 2.2 0.2 9.9 ± 0.3
ASI-2 1.9 0.2 6.9 ± 0.3
Sizes without inhibitors
Reference compounds alone 1.3 0.2 3.9 ± 0.3
Complex with 3.3 ,uM thrombin 4.9 0.4 6.9 ± 0.5
Listed are measured hydrodynamic sizes of the reference compounds
JR-Sym* and ASI-2* at high inhibitor concentrations (10-50 ,iM). The
concentration of thrombin was 5-15 ,M. For comparison, free reference
compounds and complexes between reference compounds and thrombin
without inhibitors are also listed. Experiments that show competition of an
inhibitor with the respective reference compound (i.e., the inhibitor binds
to the corresponding site) are in bold.
TABLE 2 Summary of double-labeling experiment
Binding site: Active site Exosite
Reference compound: ASI-2* Jr-Sym*
measured size measured size
Inhibitor (nm) (nm)
Rhodniin (27 ,uM) 2.1 ± 0.3 3.7 ± 0.4
Sizes without inhibitors
Reference compounds alone 1.2 ± 0.1 3.9 ± 0.2
Complex with 2.5 AM thrombin 4.6 ± 0.4 6.6 ± 0.5
Measured hydrodynamic sizes of the reference compounds at zero and at
high inhibitor concentration (27 ,uM rhodniin). The concentration of
thrombin was 2.5 ,uM.
for the free state agree reasonably well with expectations
from molecular geometry. (From crystallographic data
(Stubbs and Bode, 1993; van de Locht et al., 1995), throm-
bin is known to have an ellipsoidal shape of the approximate
dimensions 4.5 X 4.5 X 5.5 nm3. A DNA 15-mer has a
nominal linear extension of 5.4 nm (0.36 nm per base, the
ROX label, M = 515 D, has to be considered in addition).)
According to Fig. 2, the binding of the two fluorescent
reference compounds JR-Sym* and ASI-2* can be de-
scribed quantitatively by a simple two-component model.
The value of the dissociation constant of 200 nM for JR-
Sym* agrees well with a published value of 115 nM (IC50)
(Wu et al., 1992), given the uncertainties of the fit in Fig. 2.
The inability of the randomly scrambled DNA aptamer
JR-Neg* to bind to thrombin shows that the binding of
JR-Sym* is indeed a property of the sequence and not due
to unspecific binding.
Figs. 3 and 4 show that the interaction of the inhibitors
with thrombin can be monitored with FCS and that this
monitoring is site-specific. The binding of a thrombin in-
hibitor to one or both binding sites shows up as a release of
the corresponding site-specific reference labels. The bind-
ing constants of the thrombin inhibitors used in this study
are known to be in excess of 1010 M '-much greater than
the binding constants of our reference compounds. This
leads to an almost complete replacement of the reference
compounds from thrombin at inhibitor concentrations
greater than the thrombin concentration, reflected in the fact
that the observed sizes of the fluorescent reference com-
pounds JR-Sym* and ASI-2* at these inhibitor concentra-
tions are close to the sizes of the free reference compounds.
Thus quantitative information about the binding constants
of the inhibitors used cannot be obtained from our experi-
ments. This can only be done by a competition method like
the one in this study, if the binding constants of the refer-
ence compounds and the inhibitors do not differ by more
than one order of magnitude. From our experiments we can
only deduce that the inhibitors bind more strongly to throm-
bin than do our reference compounds.
The results of the double-labeling experiments show that
the two labels behave independently, i.e., when one refer-
ence label is observed with the appropriate laser wave-
length, the presence of the other reference label makes no
2199Klingler and Friedrich
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difference in the results. This behavior can be expected,
because the target protein thrombin is present in 100-fold
excess over the reference labels. At this excess of target
protein there should be no competition between the refer-
ence labels. (This excess of target protein is necessary
because of the low binding constants of the reference labels.
See Fig. 2.)
CONCLUSIONS
The results of this study show that FCS can be successfully
employed to yield quantitative information about biochem-
ical complexation reactions without separation steps. In the
system thrombin of and thrombin inhibitors, FCS together
with site-specific fluorescent reference compounds can dis-
tinguish between inhibitors directed to the active site, the
exosite, or both sites. For proteins with two binding sites,
both sites can be probed simultaneously by using reference
compounds with different fluorescence labels and distin-
guishing them spectroscopically.
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